Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

Item
http://www.wikidata.org/entity/Q30868666
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive MicroenvironmentRole of MYC in B Cell Lymphomagenesis.Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue BiopsiesFrontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series.High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a MYC-Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification.Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma.Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

Item
http://www.wikidata.org/entity/Q30868666
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@ast
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@en
type
label
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@ast
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@en
prefLabel
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@ast
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Young patients with non-germin ...... des des Lymphomes de l'Adulte/
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921